Pamela Morris, MD
Cardiovascular Disease · Charleston, SCNPI 1427166479
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $18,448 of the $22,543 with a category attached, or 81.8%. Novo Nordisk accounts for 65.6% of it on its own, with 4 other manufacturers making up the rest. Reporting peaked in 2019 at $14,799 and has fallen 79.8% since, to $2,982 in 2021. Among cardiovascular disease clinicians in SC with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 11 payments — averaging $2049.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$15K
- Amgen$5K
- Pfizer$3K
- Abbott$132
- Travere Therapeutics, Inc.$2
Across 56 payments — averaging $1110.31 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Esperion Therapeutics, Inc.$62K
What the payments were for
- Consulting fees$18,44882%
- Speaking & faculty fees$2,85013%
- Travel & lodging$1,1105%
- Food & beverage$1321%
- Education$20%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 5 | $14,798 |
| Amgen | 1 | $4,760 |
| Pfizer | 1 | $2,850 |
| Abbott | 1 | $132 |
| Travere Therapeutics, Inc. | 3 | $2 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Victoza$14,798
- Repatha$4,760
- Xience Sierra Coronary Stent System$132
How this compares
$22,543 in reported general payments places this provider in the 90th percentile of 257 cardiovascular disease providers in South Carolina.
See all cardiovascular disease providers in South Carolina →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Repatha SureclickEvolocumab | 409 | $537,883 |
| Praluent PenAlirocumab | 140 | $131,078 |
| EliquisApixaban | 38 | $43,630 |
| NexletolBempedoic Acid | 27 | $21,993 |
| Ezetimibe | 457 | $15,243 |
| Rosuvastatin Calcium | 385 | $6,127 |
| Atorvastatin Calcium | 265 | $3,703 |
| Metoprolol Succinate | 91 | $1,660 |
| Omega-3 Acid Ethyl Esters | 12 | $1,448 |
| Telmisartan | 35 | $1,186 |
| Carvedilol | 66 | $977 |
| Losartan Potassium | 62 | $935 |
| Amlodipine Besylate | 100 | $778 |
| FenofibrateFenofibrate Nanocrystallized | 32 | $778 |
| Nebivolol Hcl | 13 | $755 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $2,850 | $43,63038 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 257 cardiovascular disease providers in South Carolina.
Other cardiovascular disease in Charleston
- Robert BiedermanCharleston$775K
- Priyanka BhattacharyaCharleston$107K
- James SmithCharleston$64K
- Geetha PintoCharleston$51K
- Ian LaxinaCharleston$21K
- William YarbroughCharleston$19K
- Minh TranCharleston$18K
- Troy BuntingCharleston$16K
- Samuel PowellCharleston$10K
- Jeffrey PaulsenCharleston$10K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.